Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 178

Protein degradation as a strategy to target mutant WIP1 in ...

Close to 20% of Diffuse Intrinsic Pontine Gliomas (DIPGs) harbor a mutation in a gene called PPM1D that leads to expression of a truncated form of a protein called WIP1. We have found PPM1D-mutant DIPG cells to require expression of WIP1, rendering it an attractive therapeutic target for these ...

CHARACTERIZATION OF THE ROLE OF L3MBTL3 IN MEDULLOBLASTOMA

LAY ABSTRACT: Millions of cells are formed every day in the developing brain of children. Medulloblastoma, a pediatric tumor, occurs when the proliferation of cells in the cerebellum (a lower part of the brain) becomes uncontrolled. The Notch pathway is a key mechanism that governs cell proliferation in many biological ...

Mapping DIPG Tumour Migration using Spatial Transcriptomics

Diffuse Intrinsic Pontine Glioma (DIPG) otherwise known as Diffuse Midline Glioma (DMG) is a fatal brain stem glioma arising in young children. There are no effective therapies for DIPG and children typically succumb to the disease within 2 years. No therapy to-date has improved the survival rate for children with DIPG ...

Development of the next generation immunotherapy for diffuse midline gliomas

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive brain tumour in children. Every year, about 150-300 children in the USA and 3,000 children worldwide are diagnosed with DIPG. The prognosis of DIPG is devastating as only 10% of the patients will live for more than two years1,2. In the ...

Epigenetic reprogramming as a treatment option for NF1

Neurofibromatosis type 1 (NF1) is common, occurring in 1/3000 live births, and results in skin pigmentation and the growth of tumors along nerves in the skin, brain, and other parts of the body. It arises from a mutated and non-functional tumor suppressor bearing its name.  Tumors of the peripheral nerves, called ...